Medical News

RSS

Medicare seeks to tighten drug program rules to fight fraud

Draft regulations issued Monday would overhaul the prescription drug program and could save up to $1.3 billion over five years.

7 Jan 2014

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Fungi have played a large role in the development of many important drugs that are in wide use today. The most well-known of these are the penicillins.

7 Jan 2014

Knipper acquires MediMedia Health's sample management lines of business

J. Knipper and Company, Inc., the largest supplier of end-to-end samples management services to the U.S. pharmaceutical industry, announced today that the Company has acquired MediMedia Health's sample management lines of business. These services include direct-to- provider sample fulfillment, patient assistance programs and animal health services, as well as call center and regulatory compliance services that accompany these activities. Terms of the agreement were not disclosed.

7 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

LabStyle Innovations Corp., developer of Dario, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration for the Dario Blood Glucose Monitoring System.

7 Jan 2014

First Edition: January 7, 2014

Today's headlines include a range of reports about state developments related to the health law's online marketplaces as well as details regarding the latest Centers for Medicare & Medicaid Services' figures on health costs.

7 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

Sverica’s additional investment supports RestorixHealth's acquisition of Candescent Healing

Sverica International Management LLC, a private equity investment firm, announced today that it made an additional equity investment in RestorixHealth, a comprehensive wound care management company.

7 Jan 2014

Low gut microbial diversity in infants' intestines can increase risk for asthma

Low gut microbial diversity in the intestines of infants can increase the risk for asthma development. These are the findings of the age 7 follow-up in a multi-year study led by researchers at Linköping University in Sweden.

7 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

OMICS Group acquires International Journal of Emergency Health

OMICS Group proudly announces the acquisition of International Journal of Emergency Health, a mental health emergency or mental health crisis research based journal. IJEMH, OMICS Group's latest acquisition, is a MEDLINE indexed journal which was initiated in 1999.

7 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Europlasma to display nanocoating systems for electronic devices at CES 2014

Belgium based Europlasma, a world leader in low pressure plasma technology, is happy to present at CES 2014 its nanocoating systems for the electronics industry under the Nanofics® brand name.

7 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

Elsevier's new generation SciVal provides insights into research landscape

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of the new generation SciVal. SciVal will allow research organizations to analyze the world of research, enabling them to establish, execute and evaluate their research strategies by revealing insights based on Scopus data.

7 Jan 2014

Ihealth unveils new wearable personal health devices at CES 2014

Today, iHealth Lab Inc., announced the extension of its suite of personal mobile health devices to include a line of wearable products designed to provide monitoring over an extended period of time.

7 Jan 2014

Study identifies strategy to help women climb the academic ladder

More women are choosing science careers, yet women are notoriously underrepresented in senior academic positions—often because they abandon their careers due to pessimism about advancement. New research suggests that putting more women in decision-making roles on the teams that organize symposia could offer a simple, effective step forward.

7 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

Medical News

Medicare seeks to tighten drug program rules to fight fraud

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Knipper acquires MediMedia Health's sample management lines of business

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

LabStyle Innovations files 510(k) with FDA for Dario Blood Glucose Monitoring System

First Edition: January 7, 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

Sverica’s additional investment supports RestorixHealth's acquisition of Candescent Healing

Low gut microbial diversity in infants' intestines can increase risk for asthma

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

OMICS Group acquires International Journal of Emergency Health

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Europlasma to display nanocoating systems for electronic devices at CES 2014

Synthetic cannabinoid molecule created for osteoarthritis

Elsevier's new generation SciVal provides insights into research landscape

Ihealth unveils new wearable personal health devices at CES 2014

Study identifies strategy to help women climb the academic ladder

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News